search button

Efficacy of long‑term treatment with tenofovir in Chinese nucleos(t)ide‑naïve chronic hepatitis B patients regardless of baseline viral load

  • Authors:
    • Jie Luo
    • Xu You
    • Yutian Chong
    • Yuankai Wu
    • Jiao Gong
    • Yusheng Jie
    • Xinhua Li
    • Sujuan Xi
    • Zhiwei Zhang
    • Yufeng Zhang
    • Dongying Xie
    • Zhanyi Li
    • Xiangyong Li

  • View Affiliations

  • Published online on: May 6, 2019     https://doi.org/10.3892/etm.2019.7547
  • Pages: 260-268
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to analyze the efficacy and safety of tenofovir (TDF) treatment for up to 5 years in nucleos(t)ide‑naïve chronic hepatitis B (CHB) patients, particularly those with a high viral load, a in real‑life scenario. A total of 144 nucleos(t)ide‑naïve CHB patients who received TDF monotherapy for at least 3 months were retrospectively analyzed. The primary endpoint measure was the achievement of virological response (VR; undetectable serum HBV DNA, <100 IU/ml). The secondary endpoints were alanine aminotransferase (ALT) normalization (ALT < upper limit of normal), hepatitis B e antigen (HBeAg) seroconversion and safety. The median follow‑up period was 120 weeks (range, 12‑264 weeks). In total, 144, 130, 114, 78, 67, 40 and 13 patients were followed up for at least 12, 24, 48, 96, 144, 192 and 240 weeks, respectively. An incremental trend was observed in the rate of VR: 73.1, 91.3, 98.1, 100, 100 and 100% of the patients exhibited VR at 24, 48, 96, 144, 192 and 240 weeks, respectively. Furthermore, 29 patients with hepatitis B virus (HBV) DNA ≥8 log10 IU/ml at baseline achieved VR during the follow‑up period. The proportions of patients achieving normal ALT levels were 72.1, 78.6, 91.2, 95, 96 and 100%, at 24, 48, 96, 144, 192 and 240 weeks, respectively. The rate of HBeAg loss reached 35.6% at week 240. Among the 130 patients, HBV DNA was detectable [partial VR (PVR)] in 35 patients at 24 weeks of follow‑up, and 30 of those 35 patients (85.7%) required >24 weeks of further TDF therapy to achieve VR. No serious adverse events were reported. In conclusion, long‑term TDF treatment of nucleos(t)ide‑naïve chronic hepatitis B patients, regardless of high viral load at baseline, was effective and safe in a real‑life scenario. Adjustment of TDF monotherapy may be unnecessary in nucleos(t)ide‑naïve patients with PVR at 24 weeks.
View Figures
View References

Related Articles

Journal Cover

July-2019
Volume 18 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Luo J, You X, Chong Y, Wu Y, Gong J, Jie Y, Li X, Xi S, Zhang Z, Zhang Y, Zhang Y, et al: Efficacy of long‑term treatment with tenofovir in Chinese nucleos(t)ide‑naïve chronic hepatitis B patients regardless of baseline viral load. Exp Ther Med 18: 260-268, 2019
APA
Luo, J., You, X., Chong, Y., Wu, Y., Gong, J., Jie, Y. ... Li, X. (2019). Efficacy of long‑term treatment with tenofovir in Chinese nucleos(t)ide‑naïve chronic hepatitis B patients regardless of baseline viral load. Experimental and Therapeutic Medicine, 18, 260-268. https://doi.org/10.3892/etm.2019.7547
MLA
Luo, J., You, X., Chong, Y., Wu, Y., Gong, J., Jie, Y., Li, X., Xi, S., Zhang, Z., Zhang, Y., Xie, D., Li, Z., Li, X."Efficacy of long‑term treatment with tenofovir in Chinese nucleos(t)ide‑naïve chronic hepatitis B patients regardless of baseline viral load". Experimental and Therapeutic Medicine 18.1 (2019): 260-268.
Chicago
Luo, J., You, X., Chong, Y., Wu, Y., Gong, J., Jie, Y., Li, X., Xi, S., Zhang, Z., Zhang, Y., Xie, D., Li, Z., Li, X."Efficacy of long‑term treatment with tenofovir in Chinese nucleos(t)ide‑naïve chronic hepatitis B patients regardless of baseline viral load". Experimental and Therapeutic Medicine 18, no. 1 (2019): 260-268. https://doi.org/10.3892/etm.2019.7547